Trial
NCT04939701
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
—
Condition
Ovarian Cancer
Intervention
ASP0739
Why stopped
The comprehensive assessment of other studies indicated the lack of significant monotherapy activity, therefore, team decided to terminate the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-11